



Urs Schanz

Kontakt

Urs Schanz

Publikationen (15)

Passweg J, Baldomero H, Ansari M, Arber C, Chalandon Y, Daskalakis M, Diepold M, Diesch-Furlanetto T, Duchosal M, Gerull S, Güngör T, Heim D, Hitz F, Holbro A, Masouridi-Levrat S, Nair G, Novak U, Pabst T, Renner C, Stussi G, Schneidawind D, Schanz U, Wannesson L, Halter J, Swiss Blood Stem Cell Transplantation Group (SBST). Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997–2021. *Hematol Oncol* 2023

Dimitriou F, Cozzio A, Dummer R, French L, Hoetzenecker W, Brügger M, Kimeswenger S, Nair G, Schanz U, Guenova E. Long-Term Disease Control After Allogeneic Hematopoietic Stem Cell Transplantation in Primary Cutaneous T-Cell Lymphoma; Results From a Single Institution Analysis. *Front Med (Lausanne)* 2020; 7:290.

Ghilardi G, Ghielmini M, Wannesson L, Lerch E, Samaras P, Schanz U, Passweg J, Stussi G, Kleber M, Gerber B, Rossi D, Schmidt A, Pabst T, Jeker B, Müller R, Cairoli A, Müller A, Bargetzi M, Hitz F, Baldomero H, Heim D, Swiss Blood Stem Cell Transplantation Registry. Melphalan dose in myeloma patients ≥ 65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study. *Bone Marrow Transplant* 2018

Brügger M, French L, Hoetzenecker W, Cozzio A, Dummer R, Desislava I, Chang Y, Schanz U, Haralambieva E, Kerl K, Guenova E. Aggressive Rare T-cell Lymphomas with Manifestation in the Skin: A Monocentric Cross-sectional Case Study. *Acta Derm Venereol* 2018; 98:835–841.

Passweg J, Masouridi-Levrat S, Müller A, Nair G, Pabst T, Renner C, Schmidt A, Stussi G, Nicoloso de Faveri G, Schanz U, Leibundgut K, Hess U, Heim D, Baldomero H, Ansari M, Baerlocher G, Bargetzi M, Chalandon Y, Duchosal M, Gerull S, Güngör T, Halter J, For The Swiss Blood Stem Cell Transplantation Group Sbst. Haematopoietic cell transplantation in Switzerland, changes and results over 20 years: a report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation registry 1997–2016. *Swiss Med Wkly* 2018; 148:w14589.

Fischer A, Bastian S, Cogliatti S, Mey U, Saub J, Schanz U, Padberg S, Hohloch K. Ibrutinib-induced rapid response in chemotherapy-refractory Richter's syndrome. *Hematol Oncol* 2017

Baumgartner A, Mueller B, Stanga Z, Hess U, Duchosal M, Pabst T, Wannesson L, Limonta A, Pichard C, Chalandon Y, Samaras P, Schanz U, Passweg J, Medinger M, Zueger N, Bargetzi A, Bargetzi M, Schuetz P. Nutritional support practices in hematopoietic stem cell transplantation centers: A nationwide comparison. *Nutrition* 2016; 35:43–50.

Mehra T, Guenova E, French L, Dummer R, Hoetzenecker W, Haralambieva E, Schanz U, Nair G, Benz R, Moos R, Ikenberg K, Cozzio A. Brentuximab as a treatment for CD30+ mycosis fungoides and Sézary syndrome. *JAMA Dermatol* 2015; 151:73–7.

Terwijn M, Graux C, Bargetzi M, Legdeur M, Kuball J, de Weerd O, Chalandon Y, Hess U, Verdonck L, Gratama J, Oussoren Y, Scholten W, Slomp J, Snel A, Vekemans M, Löwenberg B, Ossenkoppele G, Wijermans P, van Gelder M, van Putten W, Kelder A, van der Velden V, Brooimans R, Pabst T, Maertens J, Boeckx N, de Greef G, Valk P, Preijers F, Huijgens P, Dräger A, Schanz U, Jongen-Lavrecic M, Biemond B, Passweg J, Schuurhuis G. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. *J Clin Oncol* 2013; 31:3889–97.

Samaras P, Renner C, Stahel R, Knuth A, Taverna C, Schäfer N, Mischo A, Schanz U, Siciliano R, Honegger H, Haile S, Buset E, Petrausch U, Zardavas D, Stenner-Liewen F. Prognostic factors for survival in lymphoma patients after autologous stem cell transplantation. *Swiss Med Wkly* 2013; 143:w13791.

Passweg J, Schanz U, Stussi G, Stern M, Renner C, Pabst T, Ozsahin H, de Faveri G, Leibundgut K, Hess U, Güngör T, Gratwohl A, Duchosal M, Chalandon Y, Bucher C, Bargetzi M, Baldomero H, SBST (Swiss Blood Stem Cell Transplantation Group). Haematopoietic stem cell transplantation: activity in Switzerland compared with surrounding European countries. *Swiss Med Wkly* 2013; 143:w13757.

Samaras P, Stenner-Liewen F, Knuth A, Bauer S, Taverna C, Stussi G, Schanz U, Honegger H, Zweifel M, Mischo A, Petrausch U, Siciliano R, Haile S, Blickenstorfer M, Renner C. Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience. *Swiss Med Wkly* 2011; 141:w13203.

Samaras P, Renner C, Knuth A, Stahel R, Stussi G, Schanz U, Pestalozzi B, Honegger H, Mischo A, Petrausch U, Haile S, Siciliano R, Buset E, Stenner-Liewen F. Equivalence of Pegfilgrastim and Filgrastim in Lymphoma Patients Treated with BEAM Followed by Autologous Stem Cell Transplantation. *Oncology* 2010; 79:93-97.

Samaras P, Stenner-Liewen F, Knuth A, Stahel R, Stussi G, Schanz U, Honegger H, Mischo A, Petrausch U, Buset E, Haile S, Siciliano R, Blickenstorfer M, Renner C. Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim. *Ann Hematol* 2010; 90:89-94.

Beyer V, van Melle G, Schmidt P, Schanz U, Laurencet F, Chapuis B, Hess U, Hitz F, Gregor M, Pugin P, Tobler A, Solenthaler M, Bougeon-Mamin S, Cabrol C, Parlier V, Mühlematter D, Jotterand M. Polysomy 8 defines a clinico-cytogenetic entity representing a subset of myeloid hematologic malignancies associated with a poor prognosis: report on a cohort of 12 patients and review of 105 published cases. *Cancer genetics and cytogenetics* 2005; 160:97-119.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch